Lumos Pharma Stock Target Price
| LUMODelisted Stock | USD 4.34 0.01 0.23% |
Lumos Pharma fundamentals help investors to digest information that contributes to Lumos Pharma's financial success or failures. It also enables traders to predict the movement of Lumos Stock. The fundamental analysis module provides a way to measure Lumos Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lumos Pharma stock.
Lumos |
Lumos Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lumos Pharma's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics of similar companies.Lumos Pharma is currently under evaluation in target price category among its peers.
Lumos Fundamentals
| Return On Equity | -1.73 | |||
| Return On Asset | -0.7 | |||
| Operating Margin | (10.52) % | |||
| Current Valuation | 24.19 M | |||
| Shares Outstanding | 8.65 M | |||
| Shares Owned By Insiders | 32.69 % | |||
| Shares Owned By Institutions | 24.27 % | |||
| Number Of Shares Shorted | 54.33 K | |||
| Price To Earning | (2.37) X | |||
| Price To Book | 7.64 X | |||
| Price To Sales | 17.02 X | |||
| Revenue | 2.05 M | |||
| Gross Profit | 1.52 M | |||
| EBITDA | (36.57 M) | |||
| Net Income | (34.03 M) | |||
| Cash And Equivalents | 79.51 M | |||
| Cash Per Share | 9.49 X | |||
| Total Debt | 585 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 17.59 X | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (31.09 M) | |||
| Short Ratio | 0.59 X | |||
| Earnings Per Share | (4.28) X | |||
| Price To Earnings To Growth | (0.15) X | |||
| Target Price | 4.25 | |||
| Number Of Employees | 30 | |||
| Beta | 0.33 | |||
| Market Capitalization | 37.54 M | |||
| Total Asset | 40.64 M | |||
| Retained Earnings | (161.52 M) | |||
| Working Capital | 33.01 M | |||
| Current Asset | 115.78 M | |||
| Current Liabilities | 14.4 M | |||
| Net Asset | 40.64 M |
About Lumos Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lumos Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lumos Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lumos Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |